Poolbeg Pharma PLC (AIM:POLB)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 24.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.71M |
| Shares Out | 697.20M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 153,084 |
| Average Volume | 1,551,123 |
| Open | 3.540 |
| Previous Close | 3.550 |
| Day's Range | 3.400 - 3.700 |
| 52-Week Range | 2.250 - 9.200 |
| Beta | 2.00 |
| RSI | 45.90 |
| Earnings Date | Sep 17, 2025 |
About Poolbeg Pharma
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated ... [Read more]
Financial Performance
Financial StatementsNews
Poolbeg Pharma PLC (POLBF) Shareholder/Analyst Call Transcript
Poolbeg Pharma PLC (OTCQB:POLBF) Shareholder/Analyst Call September 29, 2025 12:00 PM EDTCompany ParticipantsJeremy Skillington - CEO & DirectorLiam...
Poolbeg Pharma PLC (POLBF) Shareholder/Analyst Call - Slideshow
Poolbeg boss says joined-up thinking needed to foster indigenous Irish pharma sector
The chief executive of Irish clinical-stage drug firm Poolbeg Pharma, Jeremy Skillington, says Ireland has the ingredients to foster the growth of an indigenous pharmaceutical industry but still needs...
AIM Market Roundup: Poolbeg Pharma, Caledonian, Jaganda Mines
Poolbeg Pharma, Caledonian Holdings, Jaganda Mines are today's top risers, while React, Totally take the biggest fall on London's AIM market
FTSE 100 ends flat as US data dampens sentiment
FTSE 100 was flat as weak US data hit sentiment, while UK retail sales rose. Banks gained, and Poolbeg Pharma plunged. The post FTSE 100 ends flat as US data dampens sentiment appeared first on Invest...
UK Stock Market News: Standard Chartered, Poolbeg Pharma, UK Oil & Gas
New share buy back from Stan Chart, Poolbeg merger talks with HOOKIPA collapse, discounted UK O&G fundraise to back H2 storage project
AIM Market Roundup: Immupharma, Poolbeg, Xeros
ImmuPharma, Poolbeg Pharma, Xeros Technology, RBG Holdings, Coro Energy are today's biggest risers and fallers on London's AIM market
AIM Market round-up: Team Internet, Verici, Poolbeg Pharma
Team Internet, Verici, Poolbeg Pharma, Tungsten West, Global Petroleum are today's biggest risers and fallers on London's AIM market
Cathal Friels Poolbeg Pharma plunges on merger talks that would see listing move to Nasdaq
Businessman Cathal Friels Poolbeg Pharma is exploring a possible merger that would see the business shift its listing to the Nasdaq stock exchange in the US. Poolbegs shares in London plunged on the n...
Cathal Friels Poolbeg Pharma in merger talks that could land Nasdaq listing
Businessman Cathal Friels Poolbeg Pharma is exploring a possible merger that would see the business shift its listing to the Nasdaq stock exchange in the US.
Poolbeg Pharma PLC Announces Voluntary Delisting from OTCQB Market
LONDON, UK / ACCESSWIRE / July 26, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovativ...
Poolbeg Pharma PLC Announces Notification of Major Holdings
LONDON, UNITED KINGDOM / ACCESSWIRE / July 10, 2024 / TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microso...
Poolbeg Pharma PLC Announces Change of Registered Address
Change of Registered Address LONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and ...
Poolbeg Pharma PLC Announces Result of AGM
Results of Annual General Meeting LONDON, UNITED KINGDOM / ACCESSWIRE / June 17, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ‘Poolbeg' or the ‘Company'), a biopharmaceutical company focussed on the...
Poolbeg Pharma PLC Announces Annual Report & AGM Notice
LONDON, UK / ACCESSWIRE / May 9, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative...
Poolbeg Pharma PLC Announces Significant POLB 001 Patent Granted in USA
Significant POLB 001 Patent Granted in United States Immunomodulator II patent grant further strengthens robust intellectual property portfolio for partnering LONDON, UK / ACCESSWIRE / May 1, 2024 / P...
Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2023
Significant pipeline advancements Strategic expansion into cancer immunotherapy-induced CRS unlocking a market opportunity exceeding US$10Bn Key senior management hires LONDON, UK / ACCESSWIRE / April...
Poolbeg Pharma PLC Announces Appointment of Joint Broker
LONDON, UK / ACCESSWIRE / April 30, 2024 / Poolbeg Pharma Plc (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of inn...
Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate
Exclusive Option Agreement to Acquire Orphan Drug Candidate for Behçet's Disease Novel therapeutic with Fast Track and Orphan Designation LONDON, UK / ACCESSWIRE / April 30, 2024 / Poolbeg Pharma (AIM...
Poolbeg Pharma PLC Announces TR-1: Notification of Major Holdings
LONDON, UK / ACCESSWIRE / April 29, 2024 / TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word for...
Poolbeg Pharma PLC Announces POLB 001 US Patent Update
Notice of Allowance for Significant POLB 001 Patent in United States Notice of Allowance for Immunomodulator II further strengthens robust intellectual property portfolio LONDON, UK / ACCESSWIRE / Mar...
Poolbeg Pharma PLC Announces Director/PDMR Shareholding
Director Share Purchase LONDON, UK / ACCESSWIRE / February 22, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and c...
Poolbeg Pharma PLC Announces Director Share Purchase
LONDON, UK / ACCESSWIRE / February 19, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF)('Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innov...
Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP
LONDON, UK / ACCESSWIRE / February 15, 2024 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, "Poolbeg" or the "Company"), a biopharmaceutical company focussed on the development and commercialisation of innov...
Poolbeg Pharma PLC Announces Market Opportunity for POLB 001 for CRS
Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS) Former Amryt team's arrival supports inc...